Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Plc (BDRX)
Price$0.8300Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | £0 | £0 | £381,000 | £699,000 | £578,000 | £343,000 | £674,000 | £1.9M | £989,000 | £1.3M | £1.4M |
| Gross profit | −£4.0M | −£5.4M | −£3.7M | −£4.4M | — | — | — | — | £6.7M | £6.3M | £1.3M |
| Gross margin | — | — | −967.45% | −631.19% | — | — | — | — | 674.62% | 472.86% | 94.91% |
| Research & development | £4.0M | £5.4M | £4.1M | £5.1M | £4.7M | £6.1M | £7.8M | £9.4M | £8.3M | £7.7M | £8.7M |
| Operating expenses | £4.7M | £3.8M | £4.3M | £4.5M | — | — | — | — | £14.3M | £25.4M | £14.2M |
| Operating income | −£8.6M | −£9.2M | −£8.0M | −£8.9M | −£7.0M | −£23.0M | −£11.3M | −£11.8M | −£13.3M | −£9.7M | −£12.9M |
| Operating margin | — | — | −2,103.41% | −1,277.83% | −1,210.73% | −6,717.20% | −1,679.23% | −609.65% | −1,342.37% | −729.55% | −939.49% |
| EBITDA | −£6.1M | −£5.6M | −£7.2M | −£8.1M | — | — | — | −£11.7M | −£13.2M | −£9.6M | −£12.9M |
| EBITDA margin | — | — | −1,879.53% | −1,157.65% | — | — | — | −602.79% | −1,336.10% | −727.89% | −937.60% |
| Net income | −£6.4M | −£5.7M | −£7.1M | −£7.7M | −£5.5M | −£22.2M | −£10.1M | −£15.0M | −£16.1M | −£20.2M | −£10.1M |
| Net profit margin | — | — | −1,858.01% | −1,095.28% | −944.64% | −6,469.10% | −1,496.29% | −775.54% | −1,624.27% | −1,523.96% | −734.47% |
| Basic EPSper basic share | -£0.00 | -£0.00 | -£0.02 | -£1.55 | — | — | — | — | -£31.00 | -£0.56 | -£0.36 |
| Diluted EPSper diluted share | -£0.00 | -£0.00 | -£0.02 | -£1.55 | — | — | — | — | -£31.00 | -£0.56 | -£0.36 |
Insider buys & sells
Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...